Relation between Mutation in BRCA1&2 Carriers and Histopathlogical Characteristics of Breast Cancer Patients in Erbil City


Gihan H. Hamad, Salah A. Ali & Jaladet M. Jubrael

Dept. of Biology, College of Education, University of Mosul, Iraq.
Histopathology Department, Hawler Medical University, Kurdistan Region in Iraq.
Scientific Research Center, College of Science, Duhok University, Kurdistan Region in Iraq.

DOI: https://doi.org/10.17656/jzs.10556

Abstract

Mutation of breast cancer susceptibility gene1( BRCA1) and breast cancer susceptibility gene2 (BRCA2) are responsible for an increased risk of developing breast cancer. This study was planned to correlate probable occurrence of sequence variant in three exons (exon 2 and exon 20) of BRCA1 and (exon 11) of BRCA2 with other clinicopathological variables like family history, grade, stage of breast cancer. Fifty breast cancer women patients which randomly selected. The age, size of tumer, grade, stage and presence of family history were measured. Pathological analysis using H and E staining method, while conventional PCR and Direct Nucleotide Sequencing Techiques were applied for detection of BRCA1 and \ or BRCA2 mutations. Molecular analysis revealed that among 50 breast cancer patient 8 of 50 harbored deleterious mutation and 9 of 50 harbored non sense mutations. The result of these experiments also revealed that there is strong relationship between mutation and each of grade and family history, but in the same time no relation was found between mutation and stage of breast cancer.


Key Words:  PCR, sequencing, pathology of breast cancer 



References

[1] Parkin, D. M. and Coleman, M. P., "Changes in diet and changes in cancer risk, Observational studies". IARC Sci Publ, PP. 93-111. (1990).

[2] Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P., "Estimating the world cancer burden: Globocan 2000". Int. J. Cancer, Vol. 94, pp. 153-156. (2001).

[3] Ponder, B. A., "Cancer genetics", Nature, Vol. 411, pp. 336-341. (2001).

[4] Deng, C. X., "BRCA1: Cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution", Nucl. Acids Res, Vol. 34, No. 5, pp.1416-1426. (2006).

[5] McPherson, K., Steel, C. M. and Dixon, J. M., "Breast cancer epidemiology, risk factors and genetics". Br. Med. J., Vol. 321, pp. 624-628. (2000).

[6] Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., et al., "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1", Science, Vol. 266, pp. 66-71.(1994).

[7] Smith, T. M., Lee, M. K., Szabo, C. I., Jerome, N., McEuen, M., Taylor, M., Hood, L., King, M. C., "Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1", J. Med Genet, Vol. 33, pp. 889-898. (1996).

[8] Koonin, E. V, Altschul, S. F. and Bork, P., "BRCA1 protein products ... Functional motifs", Nat Genet, Vol. 13, pp. 266-268. (1996).

[9] Milner, J., Ponder, B., Hughes-Davies, L., Seltmann, M. and Kouzarides, T.,"Transcriptional activation functions in BRCA2", Nature, Vol. 386, pp. 772-773. (1997).

[10] Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C. and Micklem, G. "Identification of the breast cancer susceptibility gene BRCA2", Nature, Vol. 378, pp. 789-792. (1995).

[11] Tavtigian, S. V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., et al. "The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds", Nat Genet, Vol. 12, pp. 333-337. (1996).

[12] Narod, S. A. and Foulkes, W. D. "BRCA1 and BRCA2: 1994 and beyond". Nat Rev Cancer, Vol. 4, pp. 665-676. (2004).

[13] Davies, A. A., Masson, J. Y., McIlwraith, M. J., Stasiak, A. Z., Stasiak, A., Venkitaraman, A. R. and West, S. C., "Role of BRCA2 in control of the RAD51 recombination and DNA repair protein", Mol.Cell, Vol. 7, pp. 273-282. (2001).

[14] Rohini, R., Jarin, Ch. and Simon, N. P., "BRCA1 and BRCA2: different roles in a common pathway of genome protection", Nature, Vol. 12, pp. 68-78. (2012).

[15] Ronit, I. Y. and Moshe, Z. P. "BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions". Mol Caner Ther, Vol. 5, pp. 1396-1404. (2006).

[16] Harkin, D. P., Bean, J. M., Miklos, D., et al. "Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1", Cell, Vol. 97, pp. 575 –586. (1999).

[17] Li, S., Ting, N. S., Zheng, L., et al. "Functional link of BRCA1 and ataxiatelangiectasia gene product in DNA damage response", Nature, Vol. 406, pp. 210–215. (2000).

[18] Zhang, H., Somasundaram, K., Peng, Y., et al. "BRCA1 physically associates with p53 and stimulates its transcriptional activity", Oncogene, Vol. 16, pp. 1713–1721. (1998).

[19] Matthias, W. B., Dieter, N., Hans-George, S., Barry, A. G. A. and Hans, G. B., "Multistep carcinogenesis of breast cancer and tumor heterogeneity", J Mol Med, Vol. 75, pp. 429–439. (1997).

[20] Carlson, R.W., et al., "Breast cancer. Clinical practice guidelines in oncology", J Natl Compr Canc Netw, Vol. 7, No. 2, pp. 122-192. (2009).

[21] Staff, S., Isola, J. J., Johannsson, O., Borg, A. and Tanner, M. M., "Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa", Br J Cancer, Vol. 85, pp. 1201-1205. (2001).

[22] Armes, J. E., Trute, L., White, D., Southey, M. C., Hammet, F., et al., "Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study", Cancer Res, Vol. 59, pp. 2011-2017. (1999).

[23] Hamann, U. and Sinn, H. P., "Survival and tumor characteristics of German hereditary breast cancer patients", Breast Cancer ResTreat, Vol. 59, pp. 185-192. (2000).

[24] Evans, D. G., Howell, A. " Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?" Breast Cancer Research. Vol 6, No 1, pp. 1-4. (2004).

[25] Robson, M. E., Boyd, J., Borgen, P. I., Cody, H. S., III, "Hereditary breast cancer", Curr.Probl.Surg., Vol. 38, pp. 387-480. (2001).

[26] Foulkes, W. D., Metcalfe, K., Hanna, W., Lynch, H. T., Ghadirian, P., et al., "Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma", Cancer, Vol. 98, pp. 1569-1577. (2003).

[27] Goffin, J. R., Chappuis, P. O., Begin, L. R., Wong, N., Brunet, J. S., et al., "Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data", Cancer, Vol. 97, pp. 527-536. (2003).

[28] Sasco, J. "Epidemiology of Breast Cancer: An environmental disease". APMIS. Vol. 109, 321-332. (2001).

[29] De Leon Matsuda, M. L., Liede, A., Kwan, E., "BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines", Int J Cancer, Vol. 98, pp. 596–603. (2002).

[30] Abeer, A. Al-Mowali, Sawsan, S. Al-Haroon and Saad, A Abdualah., "Study of BRCA1 and BRCA2 Gene Mutations in Relation to Clinico-pathological Criteria of Breast Cancer in Basrah", Research Journal of Pharmaceutical, Biological and Chemical Sciences, Vol. 5, No. 5, pp. 1217-1222 (2014).

[31] Donald, E. H., Kenneth, C. C., Paul, H. L., "Histologic Grade, Stage, and Survival in Breast Carcinoma", Cancer, Vol. 98, No. 5, pp. 908-917. (2003).

[32] Mousavi, S. M., Montazeri, A., Mohagheghi, M. A., Jarrahi, A. M., Harirchi, I., "Breast cancer in Ira: An epidemiological review". The Breast Journal, Vol. 13, No. 4, pp. 383-391. (2007).

[33] Sathasivam, P., Abilasha, D., "Frequency of Various Types of Breast Lumps in Females among Malaysian Population". J. Pharm. Sci. & Res. Vol. 7, No. 10, 866-868 (2015).

[34] Zeeneldin, A. A., Ramadan, M., Elmashad, N., Fakhr, I., Diaa, A., Mosaad, E. " Breast cancer laterality among Egyptian patients and its association with treatments and survival", Journal of the Egyptian National Cancer Institute, Vol. 25, pp. 199–207. (2013).

[35] Fatima, N., Zaman, M. U., Maqbool, A., Khan, S. H., Riaz, N. " Lower Incidence but More Aggressive Behavior of Right Sided Breast Cancer in Pakistani Women: Does Right Deserve More Respect?", Asian Pacific J Cancer Prev, Vol. 14, No. 1, pp. 43-45. (2013).

[36] Elkum, N., Dermime, S., Ajarim, D., Al-Zahrani, A., Alsayed, A., et al., " Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience", BMC Cancer, Vol. 222, No. 7, pp. 1-8. (2007).

[37] Sidoni, A, Cavaliere, A, Bellezza, G, Scheibel, M, Bucciarelli, E. "Breast cancer in young women: Clinicopathological features and biological specificity". Breast, Vol. 12, pp. 247-50. (2003).

[38] Chappuis, P. O., Nethercot, V., Foulkes, W. D., "Clinico-pathological characteristics of BRCA1- and RCA2-related breast cancer", Semin Surg Oncol, Vol. 18, pp. 287-95. (2000).

[39] Al-Wajidi, F. H. A., Nile, A. K. and Ali, F. M. "The incidence of breast cancer in examined biopsies of breast masses in Al-Hussain Teaching Hospital in Kerbala". Iraqi JMS, Vol. 13, No. 1, pp. 97-102. (2015).

[40] Gowen, L. C., Johnson, B. L., Latour, A. M., Sulik, K. K., Koller, B. H. "Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities". Nat Genet, Vol. 12, No. 2, pp. 191-194. (1996).

[41] Hamad, G. H., Jubrael, J. M. S. and Omer, S. A., "Molecular detection of BRCA1 and BRCA2 in breast cancer patients in Erbil Using PCR techniques", Submitted.

[42] Gorsk,i B., Cybulski, C., Huzarski, T. et al. "Breast cancer predisposing alleles in Poland". Breast Cancer Res Treat, Vol. 92, pp. 19-24. (2005).

[43] Serrano-Fernandez, P., Debniak, T., Debniak, T., Gorski, B., Boghdanova, N. et al. "Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk". Breast Cancer Res Treat., Vol. 117, pp. 161-165. (2009).

[44] Thorslund, T., Esashi, F., West, S. C."Interactions between human BRCA2 protein and the meiosis-specific recombinase DMC1". EMBO J., Vol. 26, pp. 2915–2922. (2007).

[45] Szabo, C. I. and King, M. C. "Population genetics of BRCA1 and BRCA2". Am J. Hum Genet, Vol. 60, pp. 1013-1020. (1997).

[46] Al-Alwan, N.A.S., Al-Kubaisy, W., Al-Rawaq, K., et al. "Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer". Eastern Med Health J, WHO, EMRO, Vol. 6, No. 2/3, pp. 476. (2000).

[47] Perou, C. M., Sorlie, T., Eisen, M. B., et al, "Molecular portraits of human breast tumours". Nature, Vol. 406, pp. 747-752, (2000).

[48] Yu, K, Lee, CH, Tan, P. H., et al, "A molecular signature of the Nottingham prognostic index in breast cancer", Cancer Res, Vol. 64, pp. 2962-2968. (2004).

[49] Ivshina, A. V., George, J., Senko, O., et al, "Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer", Cancer Res, Vol. 66, pp. 10292-10301. (2006).

[50] Noori, S. F., Gangi, A., Nelson, M. E., Choi, M., Mirzadehgan, P., "Comparison of nodal metastasis between BRCA mutation carriers and non- BRCA mutation carriers with breast cancer". Annals of Surgical Oncology, Vol. 21, No. 10, pp. 3324-3329. (2014).

[51] Maksimenko, J., " The Role of Germline BRCA1 Founder Mutations and Somatic TP53 Mutations in the Triple-Negative Breast Cancer Subtype", Ph. D. Thesis, Department of Surgery and Oncology Institute, Rīga Stradiņš University.

[52] Narod, S. A. "Hormonal prevention of hereditary breast cancer". Ann N Y Acad Sci, Vol. 952, pp. 36-43. (2001).

[53] Hu, N., Wang, C., Han, X. Y., et al., "Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer". Oncogene, Vol. 23, pp. 852-858. (2004).

[54] Kaushal, M., Chattopadhyay, I., Phukan, R., et al., "Contribution of germ line BRCA2 sequence alternations to risk of familial esophageal cancer in a high-risk area of India", Dis. Esophagus, Vol. 23, pp. 71-75. (2010).